Vanguard Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$23.8M Buy
8,732,337
+206,880
+2% +$690K ﹤0.01% 2305
2026
Q2
$32M Sell
8,525,457
-207,661
-2% -$793K ﹤0.01% 2174
2026
Q1
$41M Buy
+8,733,118
New +$44.3M ﹤0.01% 1964

Other funds holding CTMX

Vanguard Capital Management's CTMX Position: Q3 2026 in Review

Vanguard Capital Management increased its CytomX Therapeutics (CTMX) stake by 2.4% in Q3 2026, buying an estimated $690K and bringing the position to 8,732,337 shares worth $23.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2305.

Vanguard Capital Management first reported a position in CTMX in Q1 2026 and has held it in 3 quarters since. The position peaked at $41M in Q1 2026. 193 funds tracked by Wall St. Rank hold CTMX as of Q3 2026.

  • Vanguard Capital Management held 8,732,337 shares of CytomX Therapeutics worth $23.8M as of Q3 2026.
  • Vanguard Capital Management bought 206,880 CytomX Therapeutics shares in Q3 2026, an estimated $690K.
  • CytomX Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2305 holding.
  • Vanguard Capital Management first reported a position in CytomX Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's CytomX Therapeutics position peaked at $41M in Q1 2026.
  • 193 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.